Owner Xencor a Delaware corporation

Service Davies Collison Cave

Various Convention priority claimed: 08 June 2001, United States of America, No. 76/268750, in respect of MEDICAL AND SCIENTIFIC RESEARCH AND DEVELOPMENT SERVICES FOR THIRD PARTIES; MEDICAL AND SCIENTIFIC CONSULTING SERVICES FOR THIRD PARTIES; PROVIDING ACCESS TO

Class 1 Biotechnological products, being pulp and paper processing enzymes, namely xylanase for bleach boosting, pitch reduction lipases, cellulases for bleach boosting; detergent enzymes, namely, detergent proteases, detergent cellulases, detergent lipases; waste remediation enzymes, namely, dehalogenase enzymes; biomass processing enzymes, namely, cellulases, amylases, and glucoamylases

Class 5 Pharmaceutical preparations for hormone replacement therapies, namely cancer gene therapy, diabetes therapy, T-Cell therapy, blood growth factors, neural growth factor therapy, anti-coagulant therapy, biological response modifier therapy, anti-cancer antibody therapy, anti-viral therapy, anti-microbial therapy; drug screening reagents, namely cytokine receptor assay reagents; and high throughput assays

Class 42 Medical and scientific research and development services for third parties; medical and scientific consulting services for third parties; providing access to databases of medical and scientific information